Prevalence, clinical characteristics, and causes of vision loss in children with Vogt-Koyanagi-Harada disease in South India
- PMID: 20168275
- DOI: 10.1097/IAE.0b013e3181c96a87
Prevalence, clinical characteristics, and causes of vision loss in children with Vogt-Koyanagi-Harada disease in South India
Abstract
Purpose: The purpose of this study was to describe the prevalence, clinical characteristics, and causes of vision loss in children with Vogt-Koyanagi-Harada disease seen at a uveitis referral center in South India.
Methods: Charts of patients with Vogt-Koyanagi-Harada disease examined in the uveitis referral clinic of Aravind Eye Hospital between January 1998 and December 2007 were reviewed. A subset of patients <or=16 years of age was identified, and the clinical characteristics and causes of vision loss were evaluated.
Results: Vogt-Koyanagi-Harada disease was diagnosed in 267 of 22,959 patients (1.2%) during the study period. Twenty-two children (8.2%) were identified, including 13 girls (59.1%) and 9 boys (40.9%). Age at presentation ranged from 8 years to 16 years, with a mean and a median of 12.6 and 13.5 years, respectively. The most common complaints were blurred vision (39 eyes, 88.6%) and eye redness (36 eyes, 81.8%). Fifteen (68.5%) children had headaches, 6 (27.3%) developed meningismus and alopecia, 4 (18.2%) developed poliosis and vitiligo, and 3 (13.6%) had tinnitus or dysacusis. Initially, all were treated with oral prednisone, but 12 (54.6%) required methotrexate, 5 (22.7%) required azathioprine, and 2 (9.1%) required cyclophosphamide. Seventy-five percent of eyes had a final visual acuity of >or=20/40, whereas 13.6% had a final visual acuity of <or=20/200.
Conclusion: Vogt-Koyanagi-Harada disease is an uncommon cause of uveitis in children. The clinical characteristics of pediatric Vogt-Koyanagi-Harada disease in South India resembled those described in cohorts from other regions. Although children in our cohort tended to do well with prompt diagnosis and treatment, long-term vision loss can occur.
Similar articles
-
Vogt-Koyanagi-Harada disease in Thai patients.J Med Assoc Thai. 2005 Nov;88 Suppl 9:S26-30. J Med Assoc Thai. 2005. PMID: 16681048
-
Vogt-Koyanagi-Harada disease in children.Eye (Lond). 2008 Sep;22(9):1124-31. doi: 10.1038/sj.eye.6702859. Epub 2007 May 4. Eye (Lond). 2008. PMID: 17479116
-
Vogt-Koyanagi-Harada disease: clinical outcomes.Am J Ophthalmol. 2005 Oct;140(4):674-8. doi: 10.1016/j.ajo.2005.04.052. Am J Ophthalmol. 2005. PMID: 16226518
-
Vogt-koyanagi-harada syndrome.Curr Eye Res. 2008 Jul;33(7):517-23. doi: 10.1080/02713680802233968. Curr Eye Res. 2008. PMID: 18600484 Review.
-
Vogt-Koyanagi-Harada syndrome in children.Ocul Immunol Inflamm. 1998 Sep;6(3):155-61. doi: 10.1076/ocii.6.3.155.4041. Ocul Immunol Inflamm. 1998. PMID: 9785605 Review.
Cited by
-
Treatment and Prognosis of Vogt-Koyanagi-Harada Disease: Real-Life Experience in Long-Term Follow-Up.J Clin Med. 2022 Jun 23;11(13):3632. doi: 10.3390/jcm11133632. J Clin Med. 2022. PMID: 35806916 Free PMC article.
-
Treatment of Vogt-Koyanagi-Harada Disease.Cureus. 2020 Jul 11;12(7):e9125. doi: 10.7759/cureus.9125. Cureus. 2020. PMID: 32789066 Free PMC article.
-
Spectrum and visual outcomes of Vogt-Koyanagi-Harada disease in Argentina.Int J Ophthalmol. 2017 Jan 18;10(1):98-102. doi: 10.18240/ijo.2017.01.16. eCollection 2017. Int J Ophthalmol. 2017. PMID: 28149784 Free PMC article.
-
Clinical spectrum and management options in Vogt-Koyanagi-Harada disease.Clin Ophthalmol. 2017 Aug 7;11:1399-1406. doi: 10.2147/OPTH.S134977. eCollection 2017. Clin Ophthalmol. 2017. PMID: 28848322 Free PMC article.
-
Update on Vertigo in Autoimmune Disorders, from Diagnosis to Treatment.J Immunol Res. 2018 Sep 26;2018:5072582. doi: 10.1155/2018/5072582. eCollection 2018. J Immunol Res. 2018. PMID: 30356417 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical